Arbidol tab p / 50 mg of the film 10 pc

Description

Composition
Active substance:
1 tablet contains: umifenovir hydrochloride monohydrate – 51.75 mg (calculated as hydrochloride umifenovir – 50.00 mg).
Excipients:
Potato starch – 31.860 mg; microcrystalline cellulose – 57.926 mg; povidone (Povidone K30) – 8.137 mg; calcium stearate – 0.535 mg; croscarmellose (sodium croscarmellose) – 1,542 mg; sheath: hypromellose (hydroxypropyl) – 4,225 mg; -1.207 mg titanium dioxide; macrogol (polyethylene glycol-4000) – 0.471 mg; polysorbate-80 (Tween-80) or -0.097 mg
Aquarius PraymBAP318008 White (Aquarius PrimeBAP318008 White) – 6,000 mg, [Hypromellose (hydroxypropyl) – 4,225 mg, titanium dioxide – 1,207 mg, macrogol (polyethylene glycol-4000) – 0.471 mg of polysorbate-80 (Tween-80) – 0.097 mg].
Description:
Tablets, film-coated, white to white with kremovatam color, round, biconvex.
At the turn from white to white with a greenish-yellow or cream color.
Product form:
Tablets, film-coated, 50 mg.
10 tablets in blisters.
10, 20, 30 or 40 tablets per polymer jar. 1, 2, 3 or 4 blisters or by the bank polimernoya 10,20,30 or 40 tablets, together with instructions for use in a stack of cardboard.
Contraindications
Hypersensitivity to umifenovir or any component of the drug, children under 3 years. The first trimester of pregnancy.
Dosage
50 mg
Indications
Prevention and treatment in adults and children: influenza A and B, and other acute respiratory viral infections.
Combined therapy of acute intestinal infection rotavirus etiology in children older than 3 years.
Combined therapy of chronic bronchitis, pneumonia, and recurrent herpetic infection.
Prevention of postoperative infectious complications.
Interaction with other drugs
In the appointment of other drugs, negative effects were noted.
Overdose
It is not checked.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacodynamics:
An antiviral agent. Specifically inhibits the in vitro influenza viruses A and B (Influenzavirus A, B), including highly subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses – pathogens of acute respiratory viral infections (ARVI) (coronavirus (Soronavirus)), associated with severe acute respiratory syndrome (SARS), rhinovirus (rhinovirus), adenovirus (adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (paramyxovirus). According to the mechanism of the antiviral action relates to inhibitors of fusion (fusion), interacts with hemagglutinin of the virus and prevent fusion of lipid shell of a virus and cellular membranes. Has a moderate immunomodulatory effect, increases resistance to viral infections. It possesses interferon-inducing activity – in the study in mice induction of interferon was observed after 16 h and remained high titers of interferon in the blood up to 48 hours after administration. It stimulates cellular and humoral immune responses: it increases the number of lymphocytes in the blood, in particular T-cells (CD3), increases the number of T-helper (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK-cells). Therapeutic efficacy for viral infections manifest in reducing the duration and severity of the disease and its main symptoms as well as reducing the incidence of complications associated with viral infection, and bacterial exacerbations of chronic diseases. It refers to preparations of low toxicity (LD50> 4 g / kg). It does not have any negative impact on the human body when administered orally in the recommended dosages.
Pharmacokinetics:
Rapidly absorbed and distributed to organs and tissues.
Maximum concentration in plasma when receiving a dose of 50 mg is achieved in 1.2 hours, in a dose of 100 mg – 1.5 hours is metabolized in the liver.. The half-life is 17-21 h. About 40% is excreted unchanged, primarily in the bile (38.9%) and the minor kidneys (0.12%). During the first day shows 90% of the administered dose.
Pregnancy and breast-feeding
In isledovanie animals showed no harmful effects on pregnancy, embryo-fetal development, labor and postnatal development.
Use of the drug Arbidol® in the first trimester of pregnancy is contraindicated. In the second and third trimester of pregnancy Arbidol® can only be used for the treatment and prevention of influenza and in the event that the anticipated benefits to the mother outweighs the potential risk to the fetus. Benefit / risk ratio is determined by the attending physician.
It is unknown whether Arbidol® passes into breast milk of lactating women. If necessary, use Arbidol® should stop breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Rarely – allergic reactions.
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
It is necessary to observe the recommended instructions circuit and duration of treatment. When you miss a single dose of the drug missed dose should be taken as a course of reception of a preparation scheme started early as possible and continue.
Effect on ability to drive and use machines:
Shows no central neurotropic activity and can be used in medical practice in people of different professions, including require attention and coordination of movements (transport drivers, operators, etc.).
Storage conditions
At a temperature of not higher than 25 C.
Dosing and Administration
Inside, before meals.
Single dose (depending on age): from 3 to 6 years-50 mg (1 tablet) from 6 to 12 years, 100 mg (2 tablets) over 12 years and adults 200 mg (4 tablets)
Sema reception:
Nonspecific prevention during influenza epidemics and ARI in single dose 2 times a week for 3 weeks.
Nonspecific prevention of direct contact with patients with influenza and other ARI in single dose one time a day for 10-14 days.
Treatment of influenza and ARI in single dose 4 times a day (every 6 hours) for 5 days
Combined therapy of acute intestinal infections rotavirus in a single dose 4 times a day (every 6 hours) for 5 days.
Complex therapy of chronic bronchitis, pneumonia, herpes infection in a single dose 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention of postoperative infectious complications in a single dose up to 2 days prior to surgery, then at 2 and 5 days after surgery.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist